Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir potassium
Drug ID BADD_D01906
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status approved
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D07133
MeSH ID D000068898
PubChem ID 23668479
TTD Drug ID D0I1FQ
NDC Product Code 62331-055; 67317-0001; 67651-0275; 70600-028; 50473-0001; 67317-0031; 65977-0129; 67651-0276; 65015-841; 67651-0274
UNII 43Y000U234
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H20FKN6O5
CAS Registry Number 871038-72-1
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Xeroderma23.01.02.003--Not Available
Tubulointerstitial nephritis20.05.02.002--Not Available
Osteopenia15.02.03.003; 14.04.04.004--Not Available
Lipodystrophy acquired23.07.01.003; 14.08.04.008--Not Available
Lymph node abscess11.01.08.031; 01.09.01.012--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Epigastric discomfort07.01.02.004--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Body fat disorder14.08.04.012--Not Available
Facial wasting23.07.01.004; 14.08.04.004--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Major depression19.15.01.003--Not Available
Dyslipidaemia14.08.04.015--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages